Blood test could unlock targeted therapy for women with hard-to-treat breast cancer

NCT ID NCT01975142

Completed Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Dec 09, 2025 · Last updated May 04, 2026 · Updated 15 times

Summary

This study looked at 155 women with metastatic breast cancer whose original tumors were HER2-negative. Researchers checked their blood for HER2-amplified circulating tumor cells. If found, participants received the drug T-DM1. The goal was to see if these blood-based markers could identify patients who might respond to a treatment not typically used for HER2-negative cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER, HER2 NEGATIVE PRIMARY TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Centre Catherine de Sienne

Vandœuvre-lès-Nancy, 54519, France
Centre Oscar Lambret

Lille, 59020, France
Centre Val d'Aurelle - P. Lamarque

Montpellier, 34298, France
Chu Saint-Louis

Paris, 75475, France
Chu de Limoges

Limoges, 87042, France
Clinique Victor Hugo

Le Mans, 72000, France
Institut Curie

Paris, 75005, France
Institut Curie - Hôpital René HUGENIN

Saint-Cloud, SAINT-CLOUD, France
Institut de Cancérologie HARTMANN

Levallois-Perret, 92309, France
Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, 54519, France

Conditions

Explore the condition pages connected to this study.

METASTATIC BREAST CANCER, HER2 NEGATIVE PRIMARY TUMOR